Cookies on Leisure Tourism

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

Leisure Tourism

Your source for all tourism, leisure and hospitality information

>>> Sign up to receive our Leisure, Hospitality & Tourism e-newsletter, book alerts, and offers <<<

Results per page:

Search results

Abstract

The combination of Atovaquone and Proguanil (MalaroneTM) has been widely used for treatment and prevention of Plasmodium falciparum malaria. Transient elevation of liver enzymes is a recognized side effect of the medication. The association of Vanishing bile duct syndrome (VBDS) with the use of...

Author(s)
Abugroun, A.; Garcia, I. C.; Ahmed, F.; Potts, S.; Flicker, M.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2019, 32, pp 101439
Abstract

The Deployment and Travel Medicine Knowledge, Attitudes, Practices, and Outcomes Study (KAPOS) examines the integrated relationship between provider and patient inputs and health outcomes associated with travel and deployments. This study describes malaria chemoprophylaxis prescribing patterns by...

Author(s)
Hickey, P. W.; Mitra, I.; Fraser, J.; Brett-Major, D.; Riddle, M. S.; Tribble, D. R.
Publisher
American Society of Tropical Medicine and Hygiene, Deerfield, USA
Citation
American Journal of Tropical Medicine and Hygiene, 2020, 103, 1, pp 334-343
Abstract

Background: Malaria during pregnancy increases the risk of maternal and foetal complications. There are very limited options for prophylaxis in pregnant travellers. Atovaquone-Proguanil (AP or Malarone®) is an effective and well-tolerated antimalarial medication, but is not recommended for use in...

Author(s)
Mayer, R. C.; Tan, K. R.; Gutman, J. R.
Publisher
Oxford University Press, Cary, USA
Citation
Journal of Travel Medicine, 2019, 26, 4, pp tay138
Abstract

Background: Malaria infection poses a significant risk in pregnancy, yet chemoprophylaxis for pregnant women is limited. A systematic review was conducted to evaluate the incidence of adverse outcomes after atovaquone-proguanil (AP) exposure during pregnancy. Methods: Following PRISMA guidelines,...

Author(s)
Andrejko, K. L.; Mayer, R. C.; Kovacs, S.; Slutsker, E.; Bartlett, E.; Tan, K. R.; Gutman, J. R.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2019, 27, pp 20-26
Abstract

Background: Poor compliance with chemoprophylaxis is a major contributing factor to the risk of malaria in travelers. Pre-travel chemoprophylaxis may improve compliance by enabling "drug-free holidays." The standard treatment dose of atovaquone/proguanil (250 mg/100 mg, 4 tablets/day for 3 days)...

Author(s)
Lau, C. L.; Ramsey, L.; Mills, L. C.; Furuya-Kanamori, L.; Mills, D. J.
Publisher
Oxford University Press, Oxford, UK
Citation
Clinical Infectious Diseases, 2019, 69, 1, pp 137-143
Abstract

Background: Travellers visiting friends and relatives (VFR) define a specific population of travellers exposed to higher risks for health and safety than tourists. The aim of this study was to assess differentials in pre-travel health care in VFR travellers compared to other travellers. Methods: A...

Author(s)
Ferrara, P.; Masuet-Aumatell, C.; Ramon-Torrell, J. M.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Public Health, 2019, 19, 1397, pp (28 October 2019)
Abstract

Clinical failure of MalaroneTM chemoprophylaxis is extremely rare. We report a case of Plasmodium falciparum malaria in a returned traveler to Ghana who fully adhered to atovaquone-proguanil (MalaroneTM) chemoprophylaxis daily dosing, yet took the pills on an empty stomach. Screening of the P....

Author(s)
Boggild, A. K.; Lau, R.; Reynaud, D.; Kain, K. C.; Gerson, M.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2015, 13, 1, pp 89-93
Abstract

Background: We evaluated existing data on the prophylactic efficacy of atovaquone-proguanil (AP) in order to determine whether prophylaxis in travellers can be discontinued on the day of return from a malaria-endemic area instead of seven days after return as per currently recommended post-travel...

Author(s)
Savelkoel, J.; Binnendijk, K. H.; Spijker, R.; Vugt, M. van; Tan, K.; Hänscheid, T.; Schlagenhauf, P.; Grobusch, M. P.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2018, 21, pp 3-20
Abstract

Background: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials. Methods: We conducted a follow-up study with a nested case-control analysis using the General...

Author(s)
Schneider, C.; Adamcova, M.; Jick, S. S.; Schlagenhauf, P.; Miller, M. K.; Rhein, H. G.; Meier, C. R.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2014, 12, 1, pp 40-47
Abstract

Malaria is still a major threat to health in tropical regions. Particular attention should be directed to malaria prevention in infants and pregnant women as they are at high risk for plasmodial infection and complicated malaria. In this review, we summarize and discuss current evidence on malaria...

Author(s)
Roggelin, L.; Cramer, J. P.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Travel Medicine and Infectious Disease, 2014, 12, 3, pp 229-236

Refine Results

Sort Order
Author
Geographical Location
Item Type
Organisms
Subject Topics